SanBio Co Ltd (SanBio) deal with the research, development, manufacture and distribution of regenerative cell medicines. The company is focusing on developing and investigating SB623, a proprietary cell-based product for the treatment of chronic traumatic brain injury, ischemic and hemorrhagic stroke; dry-age-related macular degeneration; retinitis pigmentosa; spinal cord injury; Parkinson’s and Alzheimer’s diseases. It is also developing SB618 for peripheral nerve damage; SB308 against muscle dystrophy; MSC1 for the treatment of cancer; and MSC2 targeting inflammatory diseases. The company has an operational presence in California, the US; and Singapore. SanBio is headquartered in Tokyo, Japan.
Headquarters
Japan
Address
13f, St. Luke Tower, 8-1, Akashi-Cho, Chuo-Ku, Tokyo, 104-0044
Website
www.sanbio.com
Telephone
81 3 62643481
No of Employees
65
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4592 (TYO)
EPS
XYZ
Net Income (2023)
XYZ
-18.8%
(2023 vs 2022)
Market Cap*
$226.2M
Net Profit Margin (2020)
XYZ
-192.9%
(2023 vs 2022)
* As of and is in US$
SanBio Co Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| SB623: |
| Chronic Ischemic Stroke |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Contracts/Agreements | In November, the company entered into a collaborative research agreement with the Keio University School of Medicine to explore the potential of its lead cell therapy SB623 for the treatment of Alzheimer’s disease. |
| 2021 | Corporate Changes/Expansions | In February, the company established SanBio Asia Pte. Ltd., in Singapore. |
| 2021 | Contracts/Agreements | In November, the company collaborated with D&P Bioinnovations, Inc to develop and commercialize of a medical device implant. |
Competitor Comparison
| Key Parameters | SanBio Co Ltd | Kidswell Bio Corp | Oncolys BioPharma Inc | CellSeed Inc | Healios KK |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Chuo-Ku | Chuo-Ku | Minato-Ku | Koto-Ku | Chiyoda-Ku |
| State/Province | Tokyo | Tokyo | Tokyo | Tokyo | Tokyo |
| No. of Employees | 65 | 41 | 33 | 30 | 71 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Toru Kawanishi | Chairman | Executive Board | - | - |
| Keita Mori | Chief Executive Officer; President | Executive Board | - | - |
| Andrew Liu | Chief Strategy Officer | Senior Management | 2022 | - |
| Bijan Nejadnik | Chief Medical Officer; Head - Research | Senior Management | - | - |
| Naoki Tsukahara | Business Head- Japan/Asia; Senior Corporate Officer; Corporate Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward